Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of ALNYLAM PHARMACEUTICALS, INC. from 31 Dec 2016 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
ALNYLAM PHARMACEUTICALS, INC. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Dec 2016 to 31 Mar 2025.
  • ALNYLAM PHARMACEUTICALS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Mar 2025 was $53,597,000.
  • ALNYLAM PHARMACEUTICALS, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $153,768,000.
  • ALNYLAM PHARMACEUTICALS, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $53,672,000, a 216% decline from 2022.
  • ALNYLAM PHARMACEUTICALS, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $46,403,000, a 86% decline from 2021.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $53,597,000 +$183,762,000 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q1 2024 $130,165,000 +$63,980,000 +33% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q1 2023 $194,145,000 +$91,749,000 +32% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q1 2022 $285,894,000 -$168,853,000 -144% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q1 2021 $117,041,000 -$37,806,000 -48% 01 Jan 2021 31 Mar 2021 10-Q 28 Apr 2022 2022 Q1
Q1 2020 $79,235,000 -$384,308,000 -126% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q1 2019 $305,073,000 +$554,029,000 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q1 2018 $248,956,000 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1

ALNYLAM PHARMACEUTICALS, INC. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $153,768,000 +$207,440,000 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 $53,672,000 -$100,075,000 -216% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 $46,403,000 -$276,704,000 -86% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $323,107,000 +$373,689,000 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $50,582,000 -$177,579,000 -140% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $126,997,000 +$351,198,000 01 Jan 2019 31 Dec 2019 10-K 10 Feb 2022 2021 FY
2018 $224,201,000 -$675,945,000 -150% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $451,744,000 +$439,022,000 +3451% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $12,722,000 01 Jan 2016 31 Dec 2016 10-K 14 Feb 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.